Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study

Annals of Oncology

Volumn 24, Issue 1, 2013, Pages 152-160

  Sorbye, H ^a   Welin, S ^b   Langer, S W ^c   Vestermark, L W ^d   Holt, N ^e   Osterlund, P ^f   Dueland, S ^g   Hofsli, E ^h   Guren, M G ⁱ   Ohrling, K ^j   Birkemeyer, E ^k   Thiis Evensen, E ^g   Biagini, M ^d   Gronbaek, H ^e   Soveri, L M ^f   Olsen, I H ^c   Federspiel, B ^c   Assmus, J ^a   Janson, E T ^b   Knigge, U ^c  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UPPSALA UNIVERSITY   (Sweden)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

^f HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^g OSLO UNIVERSITY HOSPITAL   (Norway)

^h TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

ⁱ ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^j KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^k STAVANGER UNIVERSITY HOSPITAL   (Norway)

more..

Author keywords

Chemotherapy; Gastrointestinal cancer; Neuroendocrine cancer; Neuroendocrine carcinoma; Predictive factors; Prognostic factors

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; ALKALINE PHOSPHATASE; C REACTIVE PROTEIN; CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; KI 67 ANTIGEN; LACTATE DEHYDROGENASE; TEMOZOLOMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; COLON TUMOR; COLORECTAL TUMOR; CONTROLLED STUDY; ESOPHAGUS TUMOR; FEMALE; GASTROINTESTINAL CARCINOMA; GASTROINTESTINAL NEUROENDOCRINE CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORPHOLOGY; MULTIPLE CYCLE TREATMENT; NEUROENDOCRINE TUMOR; PANCREAS TUMOR; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RECTUM TUMOR; RETROSPECTIVE STUDY; STOMACH TUMOR; THROMBOCYTE COUNT;

EID: 84871555750     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds276     Document Type: Article

References (34)

1. Strosberg J, Coppola D, Klimstra DS et al. The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas 2010; 39: 799-800.
2. Walenkamp AM, Sonke GS, Sleijfer DT. Clinical and therapeutic aspects of extrapulmonary small cell carcinoma. Cancer Treat Rev 2009; 35: 228-236.
3. Kloppel G, Heitz PU, Capella C et al. Pathology and nomenclature of human gastrointestinal neuroendocrine (carcinoid) tumors and related lesions. World J Surg 1996; 20: 132-141.
4. Solcia EKG, Sobin LH. Histological Typing of Endocrine Tumours. New York: Springer, 2000.
5. Bosman FT, Carneiro F, Hruban RH et al WHO Classification of Tumours of the Digestive System, 4th edition. Geneva, Switzerland: WHO Press, 2010. ISBN 978-92-832-2432-7.
6. Brenner B, Tang LH, Klimstra DS et al. Small-cell carcinomas of the gastrointestinal tract: a review. J Clin Oncol 2004; 22: 2730-2739.
7. Galanis E, Frytak S, Lloyd RV. Extrapulmonary small cell carcinoma. Cancer 1997; 79: 1729-1736.
8. Lee SS, Lee JL, Ryu MH et al. Extrapulmonary small cell carcinoma: single center experience with 61 patients. Acta Oncol 2007; 46: 846-851.
9. Shia J, Tang LH, Weiser MR et al. Is nonsmall cell type highgrade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity? Am J Surg Pathol 2008; 32: 719-731.
10. Brenner B, Tang LH, Shia J et al. Small cell carcinomas of the gastrointestinal tract: clinicopathological features and treatment approach. Semin Oncol 2007; 34: 43-50.
11. Faggiano A, Sabourin JC, Ducreux M et al. Pulmonary and extrapulmonary poorly differentiated large cell neuroendocrine carcinomas. Cancer 2007; 110: 265-274.
12. Welin S, Sorbye H, Sebjornsen S et al. Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer 2011; 11: 4617-4622.
13. Janson ET, Sorbye H, Welin S et al. Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours. Acta Oncol 2010; 49: 740-756.
14. Kang H, O'Connell JB, Leonardi MJ. Rare tumors of the colon and rectum: a national review. Int J Colorectal Dis 2007; 22: 183-189.
15. Garcia-Carbonero R, Capdevila J, Crespo-Herrero G et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol 2010; 21: 1794-1803.
16. Ahlman H, Nilsson O, McNicol AM et al. Poorly-differentiated endocrine carcinomas of midgut and hindgut origin. Neuroendocrinology 2008; 87: 40-46.
17. Nilsson O, Van Cutsem E, Delle Fave G et al. Poorly differentiated carcinomas of the foregut (gastric, duodenal and pancreatic). Neuroendocrinology 2006; 84: 212-215.
18. Brennan SM, Gregory DL, Stillie A et al. Should extrapulmonary small cell cancer be managed like small cell lung cancer? Cancer 2010; 116: 888-895.
19. NCCN Clinical practice guidelines in oncology. National Comprehensive Cancer Network (NCCN) v10, 2010. Available at www. nccn.org.
20. Moertel CG, Kvols LK, O'Connell MJ et al. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin: evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991; 68: 227-232.
21. Mitry E, Baudin E, Ducreux M et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 1999; 81: 1351-1355.
22. Sorbye H, Köhne CH, Sargent DJ et al. Patient characteristics and stratification in medical treatment studies for metastatic colorectal cancer: a proposal for standardization of patient characteristic reporting and stratification. Ann Oncol 2007; 18: 1666-1672.
23. Brenner B, Shah MA, Gonen M et al. Small-cell carcinoma of the gastrointestinal tract: a retrospective study of 64 cases. Br J Cancer 2004; 90: 1720-1726.
24. Strosberg J, Cheema A, Weber J et al. Prognostic validity of a novel American joint committee on cancer staging classification for pancreatic neuroendocrine tumors. J Clin Oncol 2011; 29: 3044-3049.
25. Bernick PE, Klimstra SD, Shia J et al. Neuroendocrine carcinomas of the colon and rectum. Dis Colon Rectum 2004; 47: 163-169.
26. Vilar E, Salazar R, Perez-Garcia J et al. Chemotherapy and role of the proliferation marker ki-67 in digestive neuroendocrine tumors. Endocr Relat Cancer 2007; 14: 221-232.
27. Lende TH, Janssen EA, Gudlaugsson E et al. In patients younger than age 55 years with lymph node-negative breast cancer, proliferation by mitotic activity index is prognostically superior to adjuvant! J Clin Oncol 2011; 29: 852-858.
28. Fujii H, Aotake T, Horiuchi T et al. Small cell carcinoma of the gallbladder: a case 45 report and review of 53 cases in the literature. Hepatogastroenterology 2001; 48: 1588-1593.
29. du Bois A, Lück HJ, Meier W et al. A randomized clinical trial of cisplatin/ paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003; 95: 1320-1329.
30. Stahel R, Thatcher N, Früh M et al. 1st ESMO consensus conference in lung cancer; Lugano 2010: small-cell lung cancer. Ann Oncol 2011; 22: 1973-1980.
31. Horwich A, Sleijfer DT, Fosså SD et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in goodprognosis metastatic nonseminomatous germ cell cancer: a multiinstitutional medical research council/European Organization for research and treatment of cancer trial. J Clin Oncol 1997; 5: 1844-1852.
32. Koukourakis MI, Giatromanolaki A, Simopoulos C et al. Lactate dehydrogenase 5 (LDH5) relates to up-regulated hypoxia inducible factor pathway and metastasis in colorectal cancer. Clin Exp Metastasis 2005; 22: 25-30.
33. Hecht JR, Trarbach T, Hainsworth JD et al. Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. J Clin Oncol 2011; 29: 1997-2003.
34. Maltoni M, Caraceni A, Brunelli C et al. Prognostic factors in advanced cancer patients: evidenced-based clinical recommendations. J Clin Oncol 2005; 23: 6240-6248.